Crystalline adipic acid salt form of a ccr6 antagonist
AssigneeIdorsia Pharmaceuticals Ltd
InventorsTony FLEISCHER, Daniel MARCHAL, Timo RAGER, Gabriel SCHAEFER, Cécilia ZOUGGARI
Life of this patent
Estimating the term…
Abstract
The present invention relates to a crystalline form of 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol adipic acid salt and its use in the treatment or prevention of various diseases or disorders such as cancer or inflammatory/autoimmune diseases or disorders.
Claims20
A crystalline form of the compound 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol adipic acid salt, wherein the crystalline form is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ:
- 6.9°, 17.8° and 19.2°.
A crystalline form of the compound 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol adipic acid salt, wherein the crystalline form is characterized by the presence of an endothermic peak in the differential scanning calorimetry thermogram at 163.5±5° C.
(canceled)
(canceled)
A process for preparing a pharmaceutical composition comprising 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol adipic acid salt, wherein said process comprises mixing a crystalline form of 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol adipic acid salt characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ:
- 6.9°, 17.8° and 19.2°, and at least one pharmaceutically acceptable carrier material.
Dependencies are inferred from the claim text.